Transactions
Dec. 18, 2001
Mintz Levin: OSI PHARMACEUTICALS WILL ADOPT FOSTER CITY COMPANY
OSI Pharmaceuticals will acquire Gilead Sciences' assets from its oncology business. OSI will acquire Gilead's clinical candidates in oncology, its intellectual property, including clinical research and drug development personnel, and its Boulder, Colo. operations. The cash and stock deal is valued at $200 million.
OSI will acquire Gilead's clinical candidates in oncology, its intellectual property, including clinical research and drug development personnel, and its Boulder, Colo. operations. The cash and stock deal is valued at $200 million.
Uniondal...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In